MED 最新10-Q变化
将 MED 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-03 与上一份 10-Q · 2026-05-04
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +70 | −78 | 0 | 0 |
| 市场风险(第3项) | 文字有新增/删除 | +32 | −14 | ~31 | 32 |
| 控制与程序 | 文字有新增/删除 | +32 | −14 | ~31 | 32 |
| 法律诉讼 | 文字有新增/删除 | +32 | −14 | ~31 | 32 |
| 风险因素 | 文字有新增/删除 | +32 | −14 | ~31 | 32 |
| 其他信息 | 文字有新增/删除 | +94 | −1 | 0 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-03
Certain information in this report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Act”). Forward-looking …
The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.
Medifast, Inc. (“Medifast,” the “Company,” “we” or “us”) is the health and wellness company known for its science-backed, comprehensive metabolic health system. In October 2025, Medifast announced its strategic transformation, unveiling its focus on holistic metabolic health. The Company started 202…
loss to address the broader metabolic health challenges impacting more than 90% of U.S. adults today. Medifast’s approach focuses on addressing the root cause of metabolic dysfunction. This strategic shift targets a larger and what is believed to be a more sustainable market, focusing on a long-term…
This growth strategy will initially be focused on improving coach productivity and expanding our coach network. We operate a well-capitalized business with a powerful lifestyle solution and a business model that has impacted over 3 million lives and, for the quarter ended June 30, 2026, had a networ…
相对上期删除的文字 · 来源:10-Q · 2026-05-04
Item 3 – Quantitative and Qualitative Disclosures about Market Risk
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds
The accompanying notes are an integral part of these condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
The accompanying notes are an integral part of these condensed consolidated financial statements.
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
Cash and cash equivalents - beginning of the period89,30390,928
相对上期删除的文字 · 来源:10-Q · 2026-05-04
Cash and cash equivalents - beginning of the period89,303 90,928
Dividends included in accounts payable and accrued expenses$206 $453
months ended March 31, 2025, an effective rate of 246.8%. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the March 31, 2026 period and the valuation allowance on the net deferred tax assets. The Company will continue to assess the realizability of its d…
The Company was in a loss position for the three months ended March 31, 2026 and 2025, and as such all awards were anti-dilutive. If the Company was not in a loss position, the calculation of diluted EPS would have included the effect of dilutive common stock equivalents of 188 thousand and 57 thous…
The total fair value of market and performance-based share awards issued during the three months ended March 31, 2026 was $0.2 million. The Company withheld approximately 8 thousand shares for the quarter ended March 31, 2026 to cover minimum tax liability withholding obligations upon the issuance o…
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
Cash and cash equivalents - beginning of the period89,30390,928
相对上期删除的文字 · 来源:10-Q · 2026-05-04
Cash and cash equivalents - beginning of the period89,303 90,928
Dividends included in accounts payable and accrued expenses$206 $453
months ended March 31, 2025, an effective rate of 246.8%. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the March 31, 2026 period and the valuation allowance on the net deferred tax assets. The Company will continue to assess the realizability of its d…
The Company was in a loss position for the three months ended March 31, 2026 and 2025, and as such all awards were anti-dilutive. If the Company was not in a loss position, the calculation of diluted EPS would have included the effect of dilutive common stock equivalents of 188 thousand and 57 thous…
The total fair value of market and performance-based share awards issued during the three months ended March 31, 2026 was $0.2 million. The Company withheld approximately 8 thousand shares for the quarter ended March 31, 2026 to cover minimum tax liability withholding obligations upon the issuance o…
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
Cash and cash equivalents - beginning of the period89,30390,928
相对上期删除的文字 · 来源:10-Q · 2026-05-04
Cash and cash equivalents - beginning of the period89,303 90,928
Dividends included in accounts payable and accrued expenses$206 $453
months ended March 31, 2025, an effective rate of 246.8%. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the March 31, 2026 period and the valuation allowance on the net deferred tax assets. The Company will continue to assess the realizability of its d…
The Company was in a loss position for the three months ended March 31, 2026 and 2025, and as such all awards were anti-dilutive. If the Company was not in a loss position, the calculation of diluted EPS would have included the effect of dilutive common stock equivalents of 188 thousand and 57 thous…
The total fair value of market and performance-based share awards issued during the three months ended March 31, 2026 was $0.2 million. The Company withheld approximately 8 thousand shares for the quarter ended March 31, 2026 to cover minimum tax liability withholding obligations upon the issuance o…
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
Cash and cash equivalents - beginning of the period89,30390,928
相对上期删除的文字 · 来源:10-Q · 2026-05-04
Cash and cash equivalents - beginning of the period89,303 90,928
Dividends included in accounts payable and accrued expenses$206 $453
months ended March 31, 2025, an effective rate of 246.8%. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the March 31, 2026 period and the valuation allowance on the net deferred tax assets. The Company will continue to assess the realizability of its d…
The Company was in a loss position for the three months ended March 31, 2026 and 2025, and as such all awards were anti-dilutive. If the Company was not in a loss position, the calculation of diluted EPS would have included the effect of dilutive common stock equivalents of 188 thousand and 57 thous…
The total fair value of market and performance-based share awards issued during the three months ended March 31, 2026 was $0.2 million. The Company withheld approximately 8 thousand shares for the quarter ended March 31, 2026 to cover minimum tax liability withholding obligations upon the issuance o…
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
The accompanying notes are an integral part of these condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
Unrealized net losses on investment securities(22)(60)(222)(1)
The accompanying notes are an integral part of these condensed consolidated financial statements.
相对上期删除的文字 · 来源:10-Q · 2026-05-04
During the three months ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议